Open AccessClinicopathologic and Radiopharmacokinetic Factors Affecting Gamma Probe–Guided Parathyroidectomy
Author(s) -
Ömer Uğur,
Murat Fani Bozkurt,
Erhan Hamaloğlu,
Cenk Sökmensüer,
Ílker Etikán,
Yeşim Uğur,
İskender Sayek,
Seza A. Güleç
Publication year - 2004
Publication title -
archives of surgery
Language(s) - English
Resource type - Journals
eISSN - 1538-3644
pISSN - 0004-0010
DOI - 10.1001/archsurg.139.11.1175
Subject(s) - medicine , gamma probe , parathyroidectomy , parathyroid hormone , thyroid , primary hyperparathyroidism , scintigraphy , hyperparathyroidism , nuclear medicine , parathyroid gland , adenoma , technetium tc 99m sestamibi , parathyroid adenoma , hyperplasia , urology , ex vivo , pathology , endocrinology , in vivo , calcium , sentinel lymph node , cancer , breast cancer , microbiology and biotechnology , biology
The kinetics of technetium Tc 99m sestamibi (MIBI) in primary hyperparathyroidism are variable and affected by the cellular size of the abnormal glands, the parathyroid hormone levels, and the functional expression of P-glycoprotein (Pgp). The success of gamma probe-guided parathyroidectomy is closely related to the parathyroid-to-thyroid activity ratio at the time of surgery. Preoperative determination of maximum uptake ratio may improve the surgical outcome.